Last reviewed 2026-05-14 · How we verify

P501-AS15 vaccine

GlaxoSmithKline · Phase 1 active Biologic

P501-AS15 vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	P501-AS15 vaccine
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

P501-AS15 vaccine CI brief — competitive landscape report
P501-AS15 vaccine updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about P501-AS15 vaccine

What is P501-AS15 vaccine?

P501-AS15 vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes P501-AS15 vaccine?

P501-AS15 vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is P501-AS15 vaccine in?

P501-AS15 vaccine is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: P501-AS15 vaccine vs similar drugs
Pricing: P501-AS15 vaccine cost, discount & access